Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Share-based Compensation (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Share-based Compensation for 6 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 30.37% to $4.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $24.0 million, a 1.68% decrease, with the full-year FY2024 number at $26.1 million, up 32.8% from a year prior.
  • Share-based Compensation was $4.5 million for Q3 2025 at 4D Molecular Therapeutics, down from $5.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.6 million in Q4 2024 to a low of $2.3 million in Q1 2021.
  • A 5-year average of $4.9 million and a median of $4.5 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 267.98% in 2021, then crashed 30.37% in 2025.
  • 4D Molecular Therapeutics' Share-based Compensation stood at $3.7 million in 2021, then grew by 16.48% to $4.3 million in 2022, then soared by 36.06% to $5.9 million in 2023, then grew by 28.16% to $7.6 million in 2024, then plummeted by 40.37% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Share-based Compensation are $4.5 million (Q3 2025), $5.0 million (Q2 2025), and $7.0 million (Q1 2025).